News and Updates
Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
Number of submitted proposals - EIC Next Generation Innovation Talents - call deadline 4 October 2023
For the EIC call Next Generation Innovation Talents (HORIZON-EIC-2023-TALENTS-01) with call deadline 4 October 2023 a number of 3 proposals was submitted.
Source: European Commission Funding and tender portal
Related News
|
2025-01-20
|
1 day ago |
Call for proposals for new EIT water now open |
|
2025-01-10
|
1 week ago |
SAFE project call for external reviewers |
|
2024-12-16
|
1 month ago |
EIT urban mobility: open call for financial support to start-ups |
|
2024-12-06
|
1 month ago |
Innonext the Next Generation Innovation Talent’s Initiative call open |
|
2024-12-04
|
1 month ago |
Evaluation results - ERC Consolidator Grant 2024 call |
|
2024-12-04
|
1 month ago |
The Strategic Technologies for Europe Platform - the STEP funding dashboard with open... |
|
2024-11-26
|
1 month ago |
Webinars for SMEs |
|
2024-11-26
|
1 month ago |
Female entrepreneurs in EU start-ups on the up but still low |
myOVERVIEW
-
sign up for personalised information
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Latest News
1517 articles available search in articlesTestimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
